Is Equinor ASA (Equinor) stock a good buy or sell?
Equinor ASA has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on 7 buy ratings, 9 hold ratings, and 3 sell ratings. According to analysts' consensus price target of $27.25, Equinor ASA has a forecasted upside of 4.3% from its current price of $26.14.
What are analysts'price targets for equillium's stock?
5 analysts have issued twelve-month price objectives for Equillium's stock. Their forecasts range from $12.00 to $18.00. On average, they anticipate Equillium's stock price to reach $14.50 in the next twelve months. This suggests a possible upside of 236.4% from the stock's current price.
How much is equillium stock worth?
One share of EQ stock can currently be purchased for approximately $4.31. How much money does Equillium make? Equillium has a market capitalization of $126.68 million. The company earns $-29.81 million in net income (profit) each year or ($1.35) on an earnings per share basis.
Who bought eqeq stock?
EQ stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Two Sigma Securities LLC, Citadel Advisors LLC, and Geode Capital Management LLC. View insider buying and selling activity for Equillium or or view top insider-buying stocks. How do I buy shares of Equillium?
Is arkema a buy?
Arkema has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 5 buy ratings, 1 hold rating, and 4 sell ratings.
Is NLOK a buy?
Out of 2 analysts, 0 (0%) are recommending NLOK as a Strong Buy, 0 (0%) are recommending NLOK as a Buy, 2 (100%) are recommending NLOK as a Hold, 0 (0%) are recommending NLOK as a Sell, and 0 (0%) are recommending NLOK as a Strong Sell.
Is Ideanomics a buy or sell?
Ideanomics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Is Meta publicly traded?
Key Takeaways. Meta (formerly Facebook) has become the dominant social media platform on the planet, with over 2.9 billion monthly active users. The company was founded in 2004 and went public via IPO on May 18, 2012, with a share price of $38.
Is Aflac stock a buy or sell?
Aflac has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 3 buy ratings, 6 hold ratings, and 1 sell rating.
Is Norton a LifeLock?
LifeLock By Norton combines the recognized Norton computer and online security name with LifeLock's reputation as a known player in identity theft protection.
Does IDEX have a future?
Ideanomics Inc (NASDAQ:IDEX) The 1 analysts offering 12-month price forecasts for Ideanomics Inc have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +321.88% increase from the last price of 0.71.
What will IDEX stock be worth in 5 years?
Although analysts don't provide long-term IDEX stock predictions on 22 March Wallet Investor's algorithm-based service predicted that the share price will trade at $0.79 by this time next year falling to $0.64 in five years.
Is IDEX a good crypto?
Is IDEX a good investment? It might be. Those who stake IDEX are rewarded with 50% of the trading fees. However, the staking token is currently down over 92% from the all-time high it reached in September 2021.
Can you buy META stock?
Buying shares of Meta Platforms is just one way of adding the company to your portfolio. You can also invest in Facebook by purchasing shares of index funds or exchange-traded funds (ETFs). Both are available through your online brokerage.
Will META be a new stock?
Meta, formerly known as Facebook, has announced it will change its stock ticker from "FB" to reflect its new name change.
Does META pay dividends?
META does not currently pay a dividend.
Is Medifast a good stock to buy?
Valuation metrics show that MEDIFAST INC may be undervalued. Its Value Score of A indicates it would be a good pick for value investors. The financial health and growth prospects of MED, demonstrate its potential to outperform the market. It currently has a Growth Score of B.
Why is NLOK stock down?
NortonLifeLock stock was dropping Tuesday after the online security software provider was downgraded by Morgan Stanley on concerns over slowing growth. Analyst Hamza Fodderwala cut his rating on NortonLifeLock (ticker: NLOK ) to Equal-weight from Overweight, while maintaining his $28 price target.
Why did NortonLifeLock stock drop?
NortonLifeLock Inc. (NLOK) dropped more than 12% on Wednesday after the U.K.'s Competition and Markets Authority (CMA) announced its intent to begin phase 2 investigations regardingNorton's proposed merger with Avast, a rival cybersecurity company.
Is Norton Antivirus publicly traded?
NortonLifeLock Inc. Sunnyvale, California, U.S. U.S. On October 9, 2014, Symantec declared it would split into two independent publicly traded companies by the end of 2015.
Should I buy or sell Equinor ASA stock right now?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Equinor ASA in the last year. There are currently 5 sell ratings, 11 hold...
What is Equinor ASA's stock price forecast for 2022?
21 Wall Street research analysts have issued 1 year target prices for Equinor ASA's stock. Their forecasts range from $19.76 to $400.00. On average...
How has Equinor ASA's stock price performed in 2022?
Equinor ASA's stock was trading at $26.33 at the beginning of 2022. Since then, EQNR stock has increased by 36.3% and is now trading at $35.89. Vi...
Are investors shorting Equinor ASA?
Equinor ASA saw a increase in short interest in May. As of May 31st, there was short interest totaling 11,030,000 shares, an increase of 55.6% from...
When is Equinor ASA's next earnings date?
Equinor ASA is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for Equinor...
How were Equinor ASA's earnings last quarter?
Equinor ASA (NYSE:EQNR) posted its earnings results on Wednesday, May, 4th. The company reported $1.60 earnings per share (EPS) for the quarter, to...
How often does Equinor ASA pay dividends? What is the dividend yield for Equinor ASA?
Equinor ASA declared a quarterly dividend on Friday, March 25th. Investors of record on Friday, May 13th will be given a dividend of $0.20 per shar...
Is Equinor ASA a good dividend stock?
Equinor ASA(NYSE:EQNR) pays an annual dividend of $0.58 per share and currently has a dividend yield of 1.57%. The dividend payout ratio of Equinor...
Who are Equinor ASA's key executives?
Equinor ASA's management team includes the following people: Mr. Anders Opedal , Pres & CEO (Age 54, Pay $1.89M) Ms. Ulrica Fearn , Exec. VP &...
About Equinor ASA
Equinor ASA engages in the exploration, production, transport, refining, and marketing of petroleum and petroleum-derived products. It operates through the following segments: Exploration and Production Norway, Exploration and Production International, Exploration and Production USA, Marketing, Midstream, and Processing, and Other.
Equinor ASA (NYSE:EQNR) Frequently Asked Questions
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Equinor ASA in the last twelve months. There are currently 5 sell ratings, 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Equinor ASA stock.
Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
Pivotal Phase 3 GEMSTONE-302 trial met key secondary endpoint of prolongation of overall survival with sugemalimab plus chemotherapy versus placebo plus chemotherapyOverall survival benefit demonstrated regardless of tumor pathologic subtype or PD-L1 expression levels CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc.
EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer
Results from the pivotal Phase 3 GEMSTONE-301 study demonstrated that sugemalimab, an anti-PD-L1 antibody, improves progression-free survival (PFS) in patients with Stage III non-small cell lung cancer (NSCLC) after sequential or concurrent chemoradiotherapy Concurrently published results from the pivotal Phase 3 GEMSTONE-302 study demonstrated PFS benefit with sugemalimab plus chemotherapy in first-line systemic treatment of patients with Stage IV NSCLC, regardless of tumor pathologic subtype o.
EQRx Enters Memorandum of Understanding with CVS Health to Create Cost Savings and Improve Patient Access to Innovative Medicines
The two companies will explore opportunities for a long-term, strategic partnership spanning the CVS Health enterpriseIncludes CVS Caremark, the leading pharmacy benefit manager in the U.S., covering 1 in 3 Americans – nearly 110 million livesInitial focus will be on EQRx’s two lead oncology programs with future therapies expected to follow CAMBRIDGE, Mass., Jan.
Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition
Equillium Inc (NASDAQ: EQ), with only one asset in its pipeline, is expanding its drug development efforts via the acquisition of Bioniz Therapeutics. The deal, worth approximately $330 million, gives the biotech access to three therapeutics.
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
LA JOLLA, Calif., February 16, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has acquired Bioniz Therapeutics, Inc., a privately held clinical-stage biotechnology company.
Equillium Provides Timing Update on Conference Presentations
LA JOLLA, Calif., February 15, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced timing updates for two separate conference presentations.
What time do you trade in the pre market?
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
Is Equinor a publicly traded company?
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2020 (54% oil) and ended the year with 5.3 billion barrels of proven reserves (51% oil). Operations also include offshore wind, oil refineries and natural gas processing, marketing, and trading.
About Equillium
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6.
Equillium (NASDAQ:EQ) Frequently Asked Questions
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Equillium in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Equillium stock. View analyst ratings for Equillium or view top-rated stocks.
45 Biggest Movers From Yesterday
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
